Dana-Farber Cancer Institute; Dana-Farber/Brigham and Women's Cancer Center; Brigham and Women's Hospital; and Harvard Medical School, Boston, MA.
J Oncol Pract. 2017 Sep;13(9):e815-e820. doi: 10.1200/JOP.2017.023788. Epub 2017 Aug 31.
Delays to adjuvant chemotherapy initiation in breast cancer may adversely affect clinical outcomes and patient satisfaction. We previously identified an association between genomic testing (Onco type DX) and delayed chemotherapy initiation. We sought to reduce the interval between surgery and adjuvant chemotherapy initiation by developing standardized criteria and workflows for Onco type DX testing.
Criteria for surgeon-initiated reflex Onco type DX testing, workflows for communication between surgeons and medical oncologists, and a streamlined process for receiving and processing Onco type DX requests in pathology were established by multidisciplinary consensus. Criteria for surgeon-initiated testing included patients ≤ 65 years old with T1cN0 (grade 2 or 3), T2N0 (grade 1 or 2), or T1/T2N1 (grade 1 or 2) breast cancer on final surgical pathology. Medical oncologists could elect to initiate Onco type testing for cases falling outside the criteria. We then examined 720 consecutive patients with breast cancer who underwent Onco type DX testing postoperatively between January 1, 2014 and November 28, 2016 and measured intervals between date of surgery, Onco type DX order date, result received date, and chemotherapy initiation date (if applicable) before and after intervention implementation.
The introduction of standardized criteria and workflows reduced time between surgery and Onco type DX ordering, and time from surgery to receipt of result, by 7.3 days ( P < .001) and 6.3 days ( P < .001), respectively. The mean number of days between surgery and initiation of chemotherapy was also reduced by 6.4 days ( P = .004).
Developing consensus on Onco type DX testing criteria and implementing streamlined workflows has led to clinically significant reductions in wait times to chemotherapy decision making and initiation.
乳腺癌辅助化疗开始时间的延迟可能会对临床结果和患者满意度产生不利影响。我们之前发现基因组检测(Onco type DX)与化疗开始时间延迟之间存在关联。我们试图通过制定标准化的 Onco type DX 检测标准和工作流程来缩短手术和辅助化疗开始之间的间隔。
通过多学科共识制定了外科医生启动反射性 Onco type DX 检测的标准、外科医生与肿瘤内科医生之间的沟通工作流程以及简化病理科接收和处理 Onco type DX 请求的流程。外科医生启动检测的标准包括:最终手术病理为 T1cN0(2 或 3 级)、T2N0(1 或 2 级)或 T1/T2N1(1 或 2 级)的年龄≤65 岁的患者。对于不符合标准的病例,肿瘤内科医生可以选择启动 Onco type 检测。然后,我们检查了 2014 年 1 月 1 日至 2016 年 11 月 28 日期间接受术后 Onco type DX 检测的 720 例连续乳腺癌患者,测量了干预实施前后手术日期、Onco type DX 订单日期、结果接收日期和(如果适用)化疗开始日期之间的间隔。
标准化标准和工作流程的引入将手术和 Onco type DX 订单之间的时间以及从手术到收到结果的时间分别缩短了 7.3 天(P<0.001)和 6.3 天(P<0.001)。手术和化疗开始之间的平均天数也减少了 6.4 天(P=0.004)。
就 Onco type DX 检测标准达成共识并实施简化工作流程,可显著减少化疗决策和启动的等待时间。